This site is intended for health professionals only
Friday 24 May 2019
Share |

Actavis launches Montelukast as patents expire in Europe

Actavis, Inc. (NYSE: ACT) has launched Montelukast tablets immediately after patent expiry in Denmark, France, Germany, Ireland, Italy, the Netherlands, Slovenia, Spain, Sweden and the UK. In Austria, Actavis started pricing and reimbursement on day 1.
The generic equivalent of Merck's Singulair®, Montelukast tablets are indicated for the treatment of asthma. Montelukast Actavis is available as regular tablets for ages 15 years and older and chewable tablets for children, 2–5 and 6–15 years old.
For the 12 months ending September 2012, Montelukast 10 mg tablets had branded and generic sales of approximately €458m in Europe, according to IMS Health data, while Montelukast chewable tablets, 4mg and 5mg, sold for about €153m during the same period.
Montelukast tablets are manufactured by Actavis in Malta.

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher